Check Cap (CHEK) Issues Earnings Results, Beats Expectations By $0.03 EPS

Check Cap (NASDAQ:CHEK) released its quarterly earnings data on Monday. The medical research company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.03, Fidelity Earnings reports.

Shares of CHEK opened at $3.79 on Tuesday. Check Cap has a 12-month low of $3.08 and a 12-month high of $19.78.

A number of analysts recently commented on the stock. HC Wainwright set a $14.00 price objective on shares of Check Cap and gave the stock a “buy” rating in a report on Tuesday. Zacks Investment Research downgraded shares of Check Cap from a “buy” rating to a “hold” rating in a report on Tuesday, July 24th.

TRADEMARK VIOLATION NOTICE: “Check Cap (CHEK) Issues Earnings Results, Beats Expectations By $0.03 EPS” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at

About Check Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.

Read More: What is a Fiduciary?

Earnings History for Check Cap (NASDAQ:CHEK)

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with's FREE daily email newsletter.

Leave a Reply